New NCCN Guidelines Stress Genetic Testing For All Pancreatic Cancer Patients (Part 2/2)
In short
New NCCN guidelines now recommend genetic testing for all pancreatic cancer patients, regardless of family history or ancestry. A landmark study found inherited mutations in six genes — including BRCA1, BRCA2, CDKN2A, TP53, MLH1, and ATM — in 5.5% of pancreatic cancer patients, many of whom would have been missed under older testing rules. Knowing your genetic results can open doors to more targeted treatments and help protect your family members too.
- •Ask your doctor to order germline genetic testing for your pancreatic cancer — the new NCCN guidelines support this for every patient, no matter your family history.
- •If a mutation like BRCA1 or BRCA2 is found, ask whether treatments such as PARP inhibitors or platinum-based drugs might be options for you.
- •If you test positive for an inherited mutation, encourage close family members to consider genetic counseling — they may qualify for cancer screening or prevention programs.
- •If insurance coverage for testing is unclear, ask your care team for help navigating it — NCCN guidelines often serve as a benchmark for coverage decisions.
Ask anything about this — free, no signup
Instant answers grounded in real guidelines, not the internet.
I think most doctors who treat pancreatic cancer patients are on board with this because of the data and because this presents a very exciting opportunity to help more people,” she adds. “The genetics are a piece of the puzzle that can help answer questions as to why this happened. We can potentially recommend targeted treatments to patients, and those treatments are getting better all the time—and we can help family members.
Highlights
from ASCO GI 2026 Survivor Stories January 28, 2026 • 3 Min Catching It Early and Moving Fast Managing Your Care January 22, 2026 • 3 Min PancChat Gets a New Home: A Podcast You Can Press “Play” On I have just been diagnosed. What should I do? Learn more Courtesy of Dana-Farber Cancer Institute.
If you or someone you love has been diagnosed with pancreatic cancer, the message is clear: all pancreatic cancer patients should undergo genetic testing for inherited genetic mutations, regardless of family history. S. that provides recommendations called Clinical Practice Guidelines for the treatment of some 30 different cancer types.
Under these new recommendations, pancreatic cancer patients should receive genetic testing for more than just the well-known BRCA1 and BRCA2 mutations, which are linked to ovarian and breast cancer, as well as pancreas and other cancers.
“Although there have been incredible leaps in the entire field of genetics, getting everyone on board with genetic testing isn’t the same thing as getting everyone on board with trying new drugs, which is a lot easier,” says gastrointestinal cancer genetics and prevention expert Dr. Sapna Syngal .
“But solid steps have been made in pancreatic cancer genetics and the data have accumulated, we believe overwhelmingly, to show that every patient with pancreatic cancer—regardless of their family history—should get germline genetic analysis,” says Syngal, who serves as Director of Research, Center for Cancer Genetics and Prevention and Director, Gastrointestinal Cancer Genetics and Prevention programs at Dana-Farber Cancer Institute in Boston, Massachusetts.
Germline Mutations Are an Important Predictor Somatic genetic mutations are random, and happen during a person’s lifetime. A germline mutation is an inherited mutation. That means a person is born with it. New research has shown just how important these germline mutations may be in pancreatic cancer development.
For example, a study published earlier this year in JAMA (Journal of the American Medical Association) showed that six genes contain mutations that may be passed down in families and substantially increase a person’s risk for pancreatic cancer. The genes include not only BRCA1 and BRCA2 but also CDKN2A, TP53, MLH1 and ATM. 2 percent of cancer patients without a family history of pancreatic cancer.
This finding led the Mayo Clinic research team to recommend genetic testing for all pancreatic cancer patients as the new standard of care.
Genetic Testing for All Prior to these new recommendations, an individual with pancreatic cancer met testing criteria only if they were of Ashkenazi ancestry or had family history of Hereditary Breast and Ovarian Cancer Syndrome (HBOC) cancers, which are most commonly caused by mutations in the BRCA1 and 2 genes, says Syngal, who along with Dana-Farber research scientist C. D.
, wrote a JAMA editorial in support of the Mayo Clinic study recommendations. However, the above groups combined account for only about 10 percent of pancreatic cancer patients. Although it’s tough to put a number on how many patients may have been affected, what is clear is that some patients fell through the cracks.
“There were a lot of pancreatic cancer patients being missed in terms of genetic testing simply because they didn’t fit into the recommendations,” says Syngal. Now, after testing, all patients will have a chance to benefit from potentially helpful targeted, more personalized, treatments.
For example, the presence of BRCA1 or BRCA2 mutations in a tumor has been found to predict response to certain therapies such as PARP inhibitors and platinum-based drugs. A patient’s family members may benefit too, adds Dr.
Syngal, since family members of a pancreatic cancer patient with a germline mutation might consider getting tested as well; family members may want to meet with a genetic counselor and learn about potential eligibility for pancreatic cancer and other cancer screening and prevention programs. It’s also important to know that having a germline mutation does not mean that you will develop pancreatic cancer, she says.
Rather, it means that you are at greater risk. What Should Patients—and their Families—Do The most important thing is to be your own advocate and “talk to your doctor, because if you have pancreatic cancer your tumor should absolutely get tested,” Syngal emphasizes. Although NCCN guidelines are a kind of “gold standard” for insurance coverage, there is sometimes a lag between new guideline recommendations and coverage.
Related pancreatic questions
- →Need recommendations for pancreatic cancer stage 4 that has spread to the liver. What treatment options are available
- →What are the must haves for someone soon to be receiving chemo by port for next 3 months, then followed by surgery?...
- →What is the real-world experience with daraxonrasib for metastatic pancreatic cancer, and how do patients tolerate it
- →What are the treatment options for Pancreatic Cancer
- →Which biomarker tests (KRAS, BRCA1/2) are recommended for my Pancreatic Cancer, and how will the results guide my...
- →What fertility preservation options exist before Pancreatic Cancer treatment in young adults
- →What is a multidisciplinary tumor board and should my Pancreatic Cancer case be presented
- →What is the 5-year survival rate for pancreatic cancer
Want to learn more about your specific case?
Upload your medical records and ask Navis questions tailored to your diagnosis.